JP2018510851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510851A5 JP2018510851A5 JP2017544916A JP2017544916A JP2018510851A5 JP 2018510851 A5 JP2018510851 A5 JP 2018510851A5 JP 2017544916 A JP2017544916 A JP 2017544916A JP 2017544916 A JP2017544916 A JP 2017544916A JP 2018510851 A5 JP2018510851 A5 JP 2018510851A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- compound
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1c(*)nnc(*)c1 Chemical compound *c1c(*)nnc(*)c1 0.000 description 16
- VUKHQPGJNTXTPY-NSCUHMNNSA-N C/C=C/Cc1ccccc1 Chemical compound C/C=C/Cc1ccccc1 VUKHQPGJNTXTPY-NSCUHMNNSA-N 0.000 description 1
- VJNJUWJHKJQYIF-UHFFFAOYSA-N CC(C)(CN(C)CC1)N1C(C)=O Chemical compound CC(C)(CN(C)CC1)N1C(C)=O VJNJUWJHKJQYIF-UHFFFAOYSA-N 0.000 description 1
- MSZXDTUUUMSSQS-UHFFFAOYSA-N CC(C)(CN(C)CC1)N1S(C)(=O)=O Chemical compound CC(C)(CN(C)CC1)N1S(C)(=O)=O MSZXDTUUUMSSQS-UHFFFAOYSA-N 0.000 description 1
- UFUZCUFUKAHDSB-IYBDPMFKSA-N CC(C)N1C[C@H](CN(Cc2ccccc2)C2)[C@H]2C1 Chemical compound CC(C)N1C[C@H](CN(Cc2ccccc2)C2)[C@H]2C1 UFUZCUFUKAHDSB-IYBDPMFKSA-N 0.000 description 1
- YGUJCUMSQULQEU-UHFFFAOYSA-N CC(C)[n]1ncc(CN2CCNCC2)c1 Chemical compound CC(C)[n]1ncc(CN2CCNCC2)c1 YGUJCUMSQULQEU-UHFFFAOYSA-N 0.000 description 1
- HNNHJSSSTNIYHO-UHFFFAOYSA-N CC(CCc1ccccc1)C(N1C(C)CN(C)CC1)=O Chemical compound CC(CCc1ccccc1)C(N1C(C)CN(C)CC1)=O HNNHJSSSTNIYHO-UHFFFAOYSA-N 0.000 description 1
- SNORQMCMXKTQSU-UHFFFAOYSA-N CC(CN(C)CC1)N1C(C1(C)COC1)=O Chemical compound CC(CN(C)CC1)N1C(C1(C)COC1)=O SNORQMCMXKTQSU-UHFFFAOYSA-N 0.000 description 1
- RKMLMSGVPZXOTA-UHFFFAOYSA-N CC(CN(C)CC1)N1C(c1cnccc1)=O Chemical compound CC(CN(C)CC1)N1C(c1cnccc1)=O RKMLMSGVPZXOTA-UHFFFAOYSA-N 0.000 description 1
- PYJUEKVBNIROGK-UHFFFAOYSA-N CC(CN(C)CC1)N1S(C1CC1)(=O)=O Chemical compound CC(CN(C)CC1)N1S(C1CC1)(=O)=O PYJUEKVBNIROGK-UHFFFAOYSA-N 0.000 description 1
- BZTWODHNEMLJEI-UHFFFAOYSA-N CC(CN(CC1)N)N1C(C(C)(C)O)=O Chemical compound CC(CN(CC1)N)N1C(C(C)(C)O)=O BZTWODHNEMLJEI-UHFFFAOYSA-N 0.000 description 1
- GCFFVKUNULPIKW-UHFFFAOYSA-N CC(N)N(CC1)CC(C)N1S(c1ccccc1)(=O)=O Chemical compound CC(N)N(CC1)CC(C)N1S(c1ccccc1)(=O)=O GCFFVKUNULPIKW-UHFFFAOYSA-N 0.000 description 1
- UESXDJWPFOVOSR-UHFFFAOYSA-N CC(N1C(Cc2ccccc2)CN(C)CC1)=O Chemical compound CC(N1C(Cc2ccccc2)CN(C)CC1)=O UESXDJWPFOVOSR-UHFFFAOYSA-N 0.000 description 1
- UZJLYRRDVFWSGA-UHFFFAOYSA-N CC(NCc1ccccc1)=O Chemical compound CC(NCc1ccccc1)=O UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 description 1
- OKNYZIGDRLPEEJ-WDEREUQCSA-N CC(N[C@H](C1)[C@@H]1c1ccccc1)=O Chemical compound CC(N[C@H](C1)[C@@H]1c1ccccc1)=O OKNYZIGDRLPEEJ-WDEREUQCSA-N 0.000 description 1
- FZLJNEILFLTBCP-UHFFFAOYSA-N CC1N(Cc2ccccc2)CCN(C)C1 Chemical compound CC1N(Cc2ccccc2)CCN(C)C1 FZLJNEILFLTBCP-UHFFFAOYSA-N 0.000 description 1
- ROBUKNKOVCATJT-UHFFFAOYSA-N CCN1CCN(Cc2c[n](C)nc2)CC1 Chemical compound CCN1CCN(Cc2c[n](C)nc2)CC1 ROBUKNKOVCATJT-UHFFFAOYSA-N 0.000 description 1
- XQLBXAYDYAWRNK-UHFFFAOYSA-N CCS(N1C(C)CN(C)CC1)(=O)=O Chemical compound CCS(N1C(C)CN(C)CC1)(=O)=O XQLBXAYDYAWRNK-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCc1ccccc1 Chemical compound CCc1ccccc1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- COJMYCSMNZBNCW-UHFFFAOYSA-N CN(C1)CC1OCc1ccccc1 Chemical compound CN(C1)CC1OCc1ccccc1 COJMYCSMNZBNCW-UHFFFAOYSA-N 0.000 description 1
- PJGCYUIHITYYHT-UHFFFAOYSA-N CN(CC1)CC(Cc2ccccc2)N1S(C)(=O)=O Chemical compound CN(CC1)CC(Cc2ccccc2)N1S(C)(=O)=O PJGCYUIHITYYHT-UHFFFAOYSA-N 0.000 description 1
- BRIWHPAJCKTPIP-UHFFFAOYSA-N CN(CC1)CC1(Cc1ccccc1)O Chemical compound CN(CC1)CC1(Cc1ccccc1)O BRIWHPAJCKTPIP-UHFFFAOYSA-N 0.000 description 1
- FLVFPAIGVBQGET-UHFFFAOYSA-N CN(CC1)CC1O Chemical compound CN(CC1)CC1O FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 1
- QRYWRVHZEBEZDQ-UHFFFAOYSA-N CN(CC1)CCN1C(c1ccccc1)=O Chemical compound CN(CC1)CCN1C(c1ccccc1)=O QRYWRVHZEBEZDQ-UHFFFAOYSA-N 0.000 description 1
- NCKYKYNYJREWCI-UHFFFAOYSA-N CN(CC1)CCN1S(c1ccccc1)(=O)=O Chemical compound CN(CC1)CCN1S(c1ccccc1)(=O)=O NCKYKYNYJREWCI-UHFFFAOYSA-N 0.000 description 1
- WQDDXVGJRSTLED-UHFFFAOYSA-N CN(CC1)CCN1c1ccccc1 Chemical compound CN(CC1)CCN1c1ccccc1 WQDDXVGJRSTLED-UHFFFAOYSA-N 0.000 description 1
- AWYQDNIZEIQOKM-UHFFFAOYSA-N CN(CCN1Cc2ccccc2)CC1=O Chemical compound CN(CCN1Cc2ccccc2)CC1=O AWYQDNIZEIQOKM-UHFFFAOYSA-N 0.000 description 1
- PZNQMJBVNDWXDY-UHFFFAOYSA-N CN(CCN1c2ccccc2)CC1=O Chemical compound CN(CCN1c2ccccc2)CC1=O PZNQMJBVNDWXDY-UHFFFAOYSA-N 0.000 description 1
- QSDUADMNMGNPLU-UHFFFAOYSA-N CN1CC(CC2)N(Cc3ccccc3)C2C1 Chemical compound CN1CC(CC2)N(Cc3ccccc3)C2C1 QSDUADMNMGNPLU-UHFFFAOYSA-N 0.000 description 1
- NJHPPXZJEYFKMD-UHFFFAOYSA-N CN1CC(Cc2ccccc2)NCC1 Chemical compound CN1CC(Cc2ccccc2)NCC1 NJHPPXZJEYFKMD-UHFFFAOYSA-N 0.000 description 1
- NNYDAONDPGWBRI-UHFFFAOYSA-N CN1CCN(Cc2cc(C#N)ccc2)CC1 Chemical compound CN1CCN(Cc2cc(C#N)ccc2)CC1 NNYDAONDPGWBRI-UHFFFAOYSA-N 0.000 description 1
- UFRQXKOKLIMLBO-UHFFFAOYSA-N CN1CCN(Cc2ccncc2)CC1 Chemical compound CN1CCN(Cc2ccncc2)CC1 UFRQXKOKLIMLBO-UHFFFAOYSA-N 0.000 description 1
- TVKCKGFYMZDMBA-STQMWFEESA-N CN1[C@@H](C2)CN(Cc3ccccc3)[C@@H]2C1 Chemical compound CN1[C@@H](C2)CN(Cc3ccccc3)[C@@H]2C1 TVKCKGFYMZDMBA-STQMWFEESA-N 0.000 description 1
- CQTKDGNXBCFBTR-LBPRGKRZSA-N C[C@@H](c1ccccc1)N1CCN(C)CC1 Chemical compound C[C@@H](c1ccccc1)N1CCN(C)CC1 CQTKDGNXBCFBTR-LBPRGKRZSA-N 0.000 description 1
- CGGBSNOQTQFSIN-UHFFFAOYSA-N C[n]1nc(CN2CCN(C)CC2)cc1 Chemical compound C[n]1nc(CN2CCN(C)CC2)cc1 CGGBSNOQTQFSIN-UHFFFAOYSA-N 0.000 description 1
- VAVNNDTVDOJAFD-UHFFFAOYSA-N Cc1nc(CN2CCN(C)CC2)c[o]1 Chemical compound Cc1nc(CN2CCN(C)CC2)c[o]1 VAVNNDTVDOJAFD-UHFFFAOYSA-N 0.000 description 1
- XBEALJJZQWXEDH-UHFFFAOYSA-N NCCN(CC1C2)C2CN1c1ncccc1 Chemical compound NCCN(CC1C2)C2CN1c1ncccc1 XBEALJJZQWXEDH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120732P | 2015-02-25 | 2015-02-25 | |
| US62/120,732 | 2015-02-25 | ||
| PCT/US2016/019328 WO2016138114A1 (en) | 2015-02-25 | 2016-02-24 | Therapeutic pyridazine compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510851A JP2018510851A (ja) | 2018-04-19 |
| JP2018510851A5 true JP2018510851A5 (enExample) | 2019-03-07 |
| JP6847844B2 JP6847844B2 (ja) | 2021-03-24 |
Family
ID=55456970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544916A Active JP6847844B2 (ja) | 2015-02-25 | 2016-02-24 | 治療用ピリダジン化合物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10308614B2 (enExample) |
| EP (1) | EP3262036B1 (enExample) |
| JP (1) | JP6847844B2 (enExample) |
| CN (1) | CN107531668B (enExample) |
| MA (1) | MA41598A (enExample) |
| WO (1) | WO2016138114A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| CN106674127A (zh) * | 2016-11-18 | 2017-05-17 | 山东友帮生化科技有限公司 | 一种n‑(6‑氯‑3‑哒嗪基)乙酰胺的合成方法 |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| CA3054682A1 (en) * | 2017-02-28 | 2018-09-07 | Epizyme, Inc. | Inhibition of smarca2 for treatment of cancer |
| WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| DK3700902T3 (en) * | 2017-10-27 | 2023-05-22 | Boehringer Ingelheim Int | Inhibitorer af trpc6 |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN112153984A (zh) * | 2018-01-30 | 2020-12-29 | 福宏治疗公司 | 化合物及其用途 |
| WO2019183523A1 (en) | 2018-03-23 | 2019-09-26 | Genentech, Inc. | Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl) |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| EP3774789B1 (en) | 2018-04-01 | 2025-03-05 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| CN112771038B (zh) * | 2018-04-26 | 2024-09-24 | 奥里吉恩发现科技有限公司 | 作为smarca2/4降解剂的哒嗪衍生物 |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CA3105748A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting nav1.8 |
| EP4219488A1 (en) | 2018-08-17 | 2023-08-02 | Novartis AG | Method for the preparation of urea compounds as smarca2/brm-atpase inhibitors |
| CN112996800B (zh) * | 2018-10-16 | 2024-06-25 | 勃林格殷格翰国际有限公司 | 作为smarca2和/或smarca4的降解剂的新型蛋白水解靶向嵌合体（protac）及其衍生物 |
| WO2020081588A1 (en) | 2018-10-17 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Swi/snf family chromatin remodeling complexes and uses thereof |
| EP3883580A4 (en) * | 2018-11-21 | 2023-01-04 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| IL285177B2 (en) * | 2019-01-29 | 2025-09-01 | Foghorn Therapeutics Inc | Compounds and their use |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| US12521438B2 (en) | 2019-06-10 | 2026-01-13 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US20220324880A1 (en) * | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US20230087825A1 (en) * | 2019-06-10 | 2023-03-23 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| PH12022550578A1 (en) | 2019-09-12 | 2024-02-19 | Aurigene Discovery Tech Ltd | Method for identifying responders to smarca2/4 degraders |
| WO2021067606A1 (en) | 2019-10-01 | 2021-04-08 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| JP2023511472A (ja) * | 2019-10-29 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二官能性化合物 |
| US12569485B2 (en) | 2019-12-23 | 2026-03-10 | Kymera Therapeutics, Inc. | SMARCA inhibitors and uses thereof |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| JP7561195B2 (ja) | 2020-01-29 | 2024-10-03 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| IL296994A (en) * | 2020-04-06 | 2022-12-01 | Foghorn Therapeutics Inc | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US11702423B2 (en) * | 2020-06-09 | 2023-07-18 | Prelude Therapeutics Incorporated | BRM targeting compounds and associated methods of use |
| CN116529250A (zh) * | 2020-08-04 | 2023-08-01 | 奥里吉恩肿瘤学有限公司 | 作为smarca2和/或smarca4降解剂的6-取代的哒嗪化合物 |
| BR112022026698A2 (pt) | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CA3195702A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| CN116867785A (zh) * | 2020-11-20 | 2023-10-10 | 福宏治疗公司 | 化合物及其用途 |
| EP4259144A4 (en) * | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| EP4289823A4 (en) * | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
| AU2022264255A1 (en) * | 2021-04-30 | 2023-11-09 | Ontario Institute For Cancer Research (Oicr) | Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
| US11993599B2 (en) | 2021-08-09 | 2024-05-28 | Genentech, Inc. | Therapeutic compounds |
| US20250049929A1 (en) | 2021-09-29 | 2025-02-13 | Boehringer Ingelheim International Gmbh | Novel tetrahydroquinolines and proteolysis targeting chimera (protacs) comprising them as degraders of smarca |
| WO2023096987A1 (en) | 2021-11-24 | 2023-06-01 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| WO2023097031A1 (en) | 2021-11-24 | 2023-06-01 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| CN118871440A (zh) * | 2022-02-09 | 2024-10-29 | 奥瑞基尼肿瘤有限公司 | 3-取代的哒嗪化合物作为smarca2和/或smarca4降解剂 |
| WO2023244806A1 (en) * | 2022-06-16 | 2023-12-21 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| CN119384414A (zh) * | 2022-06-30 | 2025-01-28 | 甘李药业股份有限公司 | 一种用作smarca2/4抑制剂的化合物及其应用 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| CN120752233A (zh) * | 2023-02-28 | 2025-10-03 | 上海海雁医药科技有限公司 | 取代的三环衍生物及其药物组合物和用途 |
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
| KR20260023037A (ko) * | 2023-06-14 | 2026-02-20 | 아스트라제네카 아베 | Smarca2 분해제 및 이의 용도 |
| AU2024303022A1 (en) * | 2023-06-16 | 2026-01-08 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| AU2024305544A1 (en) * | 2023-06-16 | 2026-01-08 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| WO2025054356A1 (en) * | 2023-09-07 | 2025-03-13 | Leapfrog Bio, Inc. | Bet inhibitors for the treatment of cancer |
| WO2025094065A1 (en) | 2023-11-01 | 2025-05-08 | Aurigene Oncology Limited | Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
| WO2025196686A1 (en) | 2024-03-20 | 2025-09-25 | Aurigene Oncology Limited | Fused bicyclic compounds as smarca2 and/or smarca4 degraders |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| FR2510997A1 (fr) * | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| EP0659439B1 (en) | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| CN1068323C (zh) | 1994-07-21 | 2001-07-11 | 阿克佐诺贝尔公司 | 环酮过氧化物配制剂 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69522717T2 (de) | 1995-03-30 | 2002-02-14 | Pfizer Inc., New York | Chinazolinderivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP0980244B1 (en) | 1997-05-06 | 2003-06-04 | Wyeth Holdings Corporation | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| KR20010031813A (ko) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도 |
| EP1131304B1 (en) | 1998-11-19 | 2002-12-04 | Warner-Lambert Company | N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| GEP20084341B (en) * | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| ATE372323T1 (de) | 2004-03-26 | 2007-09-15 | Smithkline Beecham Corp | Als antivirale mittel geeignete 4- carboxypyrazolderivate |
| RU2008141761A (ru) * | 2006-03-22 | 2010-04-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ |
| WO2011032277A1 (en) | 2009-09-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | Quinazolinone derivatives as viral polymerase inhibitors |
| EP2566858A2 (en) * | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| BR112013029640A2 (pt) * | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
-
2016
- 2016-02-23 MA MA041598A patent/MA41598A/fr unknown
- 2016-02-24 EP EP16708332.8A patent/EP3262036B1/en active Active
- 2016-02-24 CN CN201680023840.7A patent/CN107531668B/zh active Active
- 2016-02-24 JP JP2017544916A patent/JP6847844B2/ja active Active
- 2016-02-24 WO PCT/US2016/019328 patent/WO2016138114A1/en not_active Ceased
-
2017
- 2017-08-24 US US15/686,028 patent/US10308614B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510851A5 (enExample) | ||
| JP2019516757A5 (enExample) | ||
| JP2019516759A5 (enExample) | ||
| JP2017533250A5 (enExample) | ||
| JP2017530984A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| JP2018505169A5 (enExample) | ||
| JP2017525740A5 (enExample) | ||
| JP2017121233A5 (enExample) | ||
| JP2017526696A5 (enExample) | ||
| TWI482621B (zh) | 青蒿素基藥物與其他化學治療劑的抗癌組合物 | |
| WO2008120004A1 (en) | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer | |
| JP2017533249A5 (enExample) | ||
| JP2018507191A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2016529312A5 (enExample) | ||
| JP2018501287A5 (enExample) | ||
| JP2007523177A5 (enExample) | ||
| JP5903433B2 (ja) | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ | |
| JP2021169534A (ja) | 化学療法の改善 | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| JP2015214579A (ja) | 癌細胞アポトーシス | |
| JP6310470B2 (ja) | 前立腺がんを処置するための方法 | |
| JP2008536847A (ja) | ゲフィニチブ耐性患者における上皮増殖因子レセプター（ｅｇｆｒ）キナーゼインヒビターの使用 | |
| JP5858989B2 (ja) | 組合せ |